Cemdisiran

Phase 3 trial data showed poze-cemdi, a first-in-class combination treatment, helped more PNH patients achieve and maintain LDH control compared to ravulizumab, with 96% achieving adequate LDH control and 93% achieving normalization.

A Phase 3 trial found that the poze-cemdi combination treatment outperformed standard ravulizumab in disease control, measured by LDH levels. Five ravulizumab patients lacked meaningful LDH control; four improved after switching to poze-cemdi.

Regeneron's Phase 3 trial shows pozelimab and cemdisiran (poze-cemdi) combination better controls lactate dehydrogenase (LDH) levels in paroxysmal nocturnal hemoglobinuria patients compared to ravulizumab, with four out of five patients previously on ravulizumab achieving LDH control after switching to poze-cemdi.

Regeneron Pharmaceuticals announced positive Phase 3 data showing pozelimab and cemdisiran (poze-cemdi) combination treatment achieved greater disease control in PNH patients compared to ravulizumab, with 4/5 patients switching from ravulizumab achieving LDH control.

Regeneron's pozelimab and cemdisiran (poze-cemdi) combination therapy for PNH showed superior LDH control vs. ravulizumab in a Phase 3 trial, with 96% of patients achieving adequate LDH control and 93% achieving normalization. Poze-cemdi offers a four-week subcutaneous delivery and is under investigation for other complement-mediated diseases, though not yet approved.

Phase 3 trial data shows poze-cemdi combination treatment outperforms ravulizumab in controlling PNH, with better LDH level management. Poze-cemdi, a first-in-class treatment combining an antibody and siRNA targeting C5, offers potential for self-administration and improved patient outcomes.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH, with 96% achieving LDH control vs. 80% on ravulizumab. Poze-cemdi offers potential for self-administration, marking a significant advancement in PNH treatment.

Phase 3 trial data showed the poze-cemdi combination treatment outperformed standard ravulizumab in controlling PNH disease, measured by LDH levels. Poze-cemdi achieved higher LDH control and normalization rates, with a safety profile consistent with approved C5 inhibitors. A registrational cohort is ongoing to further evaluate poze-cemdi against eculizumab.